Form D · Biotechnology

CorriXR Therapeutics, Inc.

Newark, DE · CIK 0001938281

Offering snapshot reported Jan 29, 2024 · SEC filing

Reported sold
$6.53M
Offering amount: $8.03M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 30, 2022
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$3.26M$6.53MJul 15, 2022: $2,499,998.00Jul 15, 2022Jan 29, 2024: $6,525,179.00Jan 29, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$2,499,998 → $6,525,179
  • Reported investors1 → 4

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 29, 2024Amendment$6,525,179$4,025,181vs Jul 15, 20224SEC filing
Jul 15, 2022Initial$2,499,998No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-452572

Source: Form D, filed Jan 29, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Jon Brilliant Executive
Jeffrey Carper Director
Eric Kmiec Director, Executive
Deborah Moorad Director, Executive
Janice Nevin Director
Stella Vnook Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
550 S. College Avenue, Suite 107
Newark, DE, 19713